GILD : Analysis & Opinions

  • Showing 101-131 of 131 items
  • <<
  • 1
  • 2
  1. Vertex Building A Fortress In Cystic Fibrosis

    August 28, 2013
    Vertex is in the early days of what could be a $10B franchise in cystic fibrosis treatment.
  2. Wall Street Happy To Hum La AbbVie En Rose

    July 26, 2013
    AbbVie's pipeline is better than some think, but valuation is no particular bargain right now.
  3. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  4. Roche, Reloaded

    May 21, 2013
    Roche has one of the best long-term growth profiles in the Big Pharma space
  5. Amgen Chased By The Bubble

    May 8, 2013
    Amgen really needs the pipeline to come through to support this valuation.
  6. The Smart Money Loves These 10 Stocks

    January 14, 2013
    During the past 10 years, the best hedge funds have consistently produced market-beating returns, driving huge capital inflows ...
  7. Healthcare Stocks, Including Gilead, Making Big Moves on October ...

    October 24, 2012
    So far today, the Nasdaq remains relatively unchanged, the S&amp;P 500 has risen 0.1% and the Dow has climbed 0.3%. The healthcare ...
  8. 15 Biotech Companies Waiting For FDA Approval

    March 21, 2012
    Despite all of these uncertainties, investors still heavily focus on whether a company's new drug will be approved by the ...
  9. Hanesbrands Still A Good Fit

    February 21, 2012
    The long-term appeal of Hanesbrands' business is still there, provided management delivers on its promise to reduce debt.
  10. Playing A Biotech Breakout

    February 15, 2012
    Strong pipelines for the biotech sector as well as a wave of merger activity, have investors flocking to the stocks.
  11. Big Bets on High-Flying Pharma Stock

    February 9, 2012
    Following bullish earnings, Karee Venema of Schaeffer’s Research writes that call buyers are piling in to one biopharmaceutical ...
  12. 2011's Biggest Mergers and Acquisitions

    December 30, 2011
    M&amp;A activity rebounded in a big way in 2011. Here's a look back at the biggest mergers and acquisitions during the year.
  13. Is Third Time The Charm For Gilead?

    November 22, 2011
    Gilead is going all in on Hep C, as it acquires Pharmasset in a massive deal.
  14. A Deal At Last For Sanofi And Genzyme

    February 18, 2011
    Though Sanofi finally got its way in acquiring Genzyme, time will determine if stockholders will truly benefit.
  15. InterMune - The Black Knight Of Biotech?

    December 21, 2010
    Possible European approval could save the day for this risky biotech.
  16. 4 Cheap, High-Quality Stocks

    September 23, 2010
    Stocks trading below the S&amp;P 500 P/E average are cheap, but are they a good buy?
  17. Bristol-Myers Pays A Premium For Its Partner

    September 10, 2010
    Bristol-Myers is paying a lot, but a successful HCV franchise could be worth much more.
  18. 5 Stocks Hitting Bottom

    July 29, 2010
    Making bets on stocks that have been driven down too far can be a great way to catch some of the next batch of winners.
  19. Getting In On Growth At A Great Price

    July 5, 2010
    Here are some growth-oriented stocks with below-market average P/Es that investors can pick up during this shaky market to ...
  20. There Is Life After Death, At Least In Biotech

    June 22, 2010
    Clinical failure is not the end of the story for all biotechs. How do some survive while others disappear?
  21. Biotech Bargains

    June 17, 2010
    High-growth biotech stocks are now priced like value plays.
  22. FDA Makes InterMune Sick

    May 10, 2010
    Should investors hang on despite a devastating FDA decision?
  23. 5 Stocks From McDonald's Portfolio

    April 27, 2010
    Take a look inside the profit sharing and savings portfolio McDonald's runs for its employees.
  24. Stocks That Institutional Investors Love

    February 4, 2010
    Looking at the stocks that institutional investors own can provide a good starting point for the everyday investor.
  25. Earnings Winners You Shouldn't Miss

    January 29, 2010
    Plenty of companies have posted disappointing results for last quarter, but a few off-the-radar names have done surprisingly ...
  26. The Best Performing Stocks Of The Decade

    June 9, 2009
    Investors who were able to see past the losses and volatility that some of these companies had in the beginning were amply ...
  27. Is Now The Time To Buy Pharmaceuticals?

    May 5, 2009
    Despite the recession, the pharmaceutical sector continues to show strong year-over-year earnings results and demand worldwide.
  28. Money Flowing Into Biotech Stocks

    January 12, 2009
    Institutions have their eyes on biotech stocks. Does this sector have your attention?
  29. Biotech ETFs Under The Microscope

    July 24, 2008
    Biotech ETFs have been immune to the falling stock market. We examine three top performing funds to find a surprising long-term ...
  30. Getting Technical With Biotech

    July 11, 2008
    Watch as a blend of technical and fundamental analysis reveals hidden gems in this unpredictable sector.
  31. Gilead Is A Winner (GILD)

    June 15, 2007
    With its successful product pipeline, Gilead shines among biotechs, and its future is only getting brighter.
  • Showing 101-131 of 131 items
  • <<
  • 1
  • 2
Trading Center